Title: Activation of the Nrf2-ARE pathway by the Alternaria alternata mycotoxins altertoxin I and II.
Journal: Archives of toxicology20170101
Title: Generation of a New Model Rat: Nrf2 Knockout Rats Are Sensitive to Aflatoxin B1 Toxicity.
Journal: Toxicological sciences : an official journal of the Society of Toxicology20160701
Title: Identification of modulators of the nuclear receptor peroxisome proliferator-activated receptor α (PPARα) in a mouse liver gene expression compendium.
Journal: PloS one20150101
Title: Genetic or pharmacologic activation of Nrf2 signaling fails to protect against aflatoxin genotoxicity in hypersensitive GSTA3 knockout mice.
Journal: Toxicological sciences : an official journal of the Society of Toxicology20140601
Title: Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO.
Journal: PloS one20140101
Title: Validation of the multiple sensor mechanism of the Keap1-Nrf2 system.
Journal: Free radical biology & medicine20120815
Title: Synthetic triterpenoids, CDDO-Imidazolide and CDDO-Ethyl amide, induce chondrogenesis.
Journal: Osteoarthritis and cartilage20120501
Title: Pharmacological induction of heme oxygenase-1 by a triterpenoid protects neurons against ischemic injury.
Journal: Stroke20120501
Title: Implementation of a high-throughput screen for identifying small molecules to activate the Keap1-Nrf2-ARE pathway.
Journal: PloS one20120101
Title: Synthesis and biological evaluation of 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4-ethynylimidazole. A novel and highly potent anti-inflammatory and cytoprotective agent.
Journal: Bioorganic & medicinal chemistry letters20110415
Title: CDDO-Im is a stimulator of megakaryocytic differentiation.
Journal: Leukemia research20110401
Title: CDDO-Im, an antitumor molecule that also improves platetet production.
Journal: Leukemia research20110401
Title: Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.
Journal: Journal of medicinal chemistry20110324
Title: The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis.
Journal: Clinical & experimental metastasis20110301
Title: Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR.
Journal: PloS one20110101
Title: Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via nuclear factor-kappa B.
Journal: PloS one20110101
Title: Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity.
Journal: The Journal of pharmacology and experimental therapeutics20101001
Title: Synthetic triterpenoids target the Arp2/3 complex and inhibit branched actin polymerization.
Journal: The Journal of biological chemistry20100903
Title: Synthetic triterpenoids inhibit growth, induce apoptosis and suppress pro-survival Akt, mTOR and NF-{kappa}B signaling proteins in colorectal cancer cells.
Journal: Anticancer research20100301
Title: Active NF-E2-related factor (Nrf2) contributes to keep endothelial NO synthase (eNOS) in the coupled state: role of reactive oxygen species (ROS), eNOS, and heme oxygenase (HO-1) levels.
Journal: The Journal of biological chemistry20091113
Title: The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice.
Journal: American journal of respiratory and critical care medicine20091101
Title: Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide.
Journal: European journal of pharmacology20091012
Title: Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6.
Journal: Proceedings of the National Academy of Sciences of the United States of America20090929
Title: High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolide.
Journal: Cancer letters20090918
Title: Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice.
Journal: Carcinogenesis20090601
Title: CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes.
Journal: Toxicology and applied pharmacology20090401
Title: CDDO-imidazolide mediated inhibition of malignant cell growth in Waldenström macroglobulinemia.
Journal: Leukemia research20081201
Title: Coordinated induction of Nrf2 target genes protects against iron nitrilotriacetate (FeNTA)-induced nephrotoxicity.
Journal: Toxicology and applied pharmacology20080915
Title: A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin.
Journal: Cancer research20080815
Title: Resistance of acute myeloid leukemic cells to the triterpenoid CDDO-Imidazolide is associated with low caspase-8 and FADD levels.
Journal: Leukemia research20080801
Title: Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development.
Journal: Hepatology (Baltimore, Md.)20080801
Title: Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice.
Journal: Toxicological sciences : an official journal of the Society of Toxicology20080701
Title: Synthetic triterpenoids have cytotoxicity in pediatric acute lymphoblastic leukemia cell lines but cytotoxicity is independent of induced ceramide increase in MOLT-4 cells.
Journal: Leukemia20080601
Title: The synthetic triterpenoid CDDO-Im inhibits fatty acid synthase expression and has antiproliferative and proapoptotic effects in human liposarcoma cells.
Journal: Cancer investigation20080301
Title: Immunomodulatory activity of synthetic triterpenoids: inhibition of lymphocyte proliferation, cell-mediated cytotoxicity, and cytokine gene expression through suppression of NF-kappaB.
Journal: Immunopharmacology and immunotoxicology20080101
Title: Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils.
Journal: Antioxidants & redox signaling20071101
Title: Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NF-kappaB and Notch1 signaling.
Journal: Journal of neuro-oncology20070901
Title: Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: highly potent anti-inflammatory and cytoprotective agents.
Journal: Journal of medicinal chemistry20070419
Title: Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes.
Journal: Molecular cancer therapeutics20070101
Title: Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide.
Journal: Biochemical and biophysical research communications20061229
Title: The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta.
Journal: Molecular cancer therapeutics20061201
Title: The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20060715
Title: The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells.
Journal: Molecular cancer therapeutics20060601
Title: Microsphere-based protease assays and screening application for lethal factor and factor Xa.
Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology20060501
Title: A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20060315
Title: Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole.
Journal: Cancer research20060215
Title: 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer.
Journal: The Journal of biological chemistry20051028
Title: The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling.
Journal: Cancer research20050601
Title: Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
Journal: Cancer research20050601
Title: Triterpenoid CDDO-Im downregulates PML/RARalpha expression in acute promyelocytic leukemia cells.
Journal: Cell death and differentiation20050501
Title: Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias.
Journal: Molecular cancer therapeutics20041001
Title: The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
Journal: Blood20040415
Title: Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid.
Journal: Molecular cancer therapeutics20040101
Title: The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20030701
Title: Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling.
Journal: Cancer research20030315
Title: A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production.
Journal: Bioorganic & medicinal chemistry letters20020408
Title: Place AE, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res. 2003 Jul;9(7):2798-806.
Title: Liby K, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 2005 Jun 1;65(11):4789-98.
Title: So JY, et al. A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer. PLoS One. 2014 Sep 17;9(9):e107616.
